Informação sobre produto
- Leflunomide Imp. B (EP)
- (2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide
- (2Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-Butenamide
- 2-Butenamide
- 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-
- (Z)-
- A 1726
- A 771726
- Aubagio
- Flucyamide
- Ver mais sinónimos
- HMR 1726
- SU 20
- Teriflunomide
- Leflunomide Impurity B
- (2Z)-2-(hydroxy{[4-(trifluoromethyl)phenyl]amino}methylidene)-3-oxobutanenitrile
- (2Z)-2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide
- (Z)-2-Cyano-alpha'alpha'alpha-trifluoro-3-hydroxy-p-crotonotoluidide
- 2-Butenamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-
- 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (2Z)-
- 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (Z)-
- 2-Cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide
- A771726
- Active metabolite of leflunomide
- Femorix
- Hmr 1726
- Malononitrilamide
- N-(4-Trifluoromethylphenyl)-2-cyano-2-hydroxycrotonamide
- Su 20
- Teriflunomide [INN]
- Unii-1C058Ikg3B
Impurity Leflunomide EP Impurity B
Applications A77 1726 (Leflunomide EP Impurity B) is the active metabolite of Leflunomide, a potent disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis. LEF-M interferes with dendritic cell function. The second Phase III study evaluating the efficacy of Genzyme’s teriflunomide therapy against relapsing forms of multiple sclerosis found the once-daily oral drug to be no less effective than injectable interferon beta 1a (Rebif®).
References Kirsch, B.M., et al.: Arthritis Research and Therapy, 7, 3, R694, (2005)
Propriedades químicas
Consulta técnica sobre: TR-A771726 A 77-1726
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.